Obiltoxaximab prevents disseminated Bacillus anthracis infection and improves survival during pre- and postexposure prophylaxis in animal models of inhalational anthrax

Antimicrobial Agents and Chemotherapy

Volumn 60, Issue 10, 2016, Pages 5796-5805

  Yamamoto, Brent J ^a,c   Shadiack, Annette M ^a,d   Carpenter, Sarah ^a,e   Sanford, Daniel ^b   Henning, Lisa N ^b   Gonzales, Nestor ^a,g   O'Connor, Edward ^a,f   Casey, Leslie S ^a   Serbina, Natalya V ^a  

^a Elusys Therapeutics Inc   (United States)

^b BATTELLE MEMORIAL INSTITUTE   (United States)

^c BRISTOL MYERS SQUIBB   (United States)

^d TherapeuticsMD   (United States)

^e MERCK RESEARCH LABORATORIES   (United States)

^f LOVELACE RESPIRATORY RESEARCH INSTITUTE   (United States)

^g VERTEX PHARMACEUTICALS   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

LEVOFLOXACIN; OBILTOXAXIMAB; ANTIINFECTIVE AGENT; ANTITOXIN; MONOCLONAL ANTIBODY;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTHRAX; ARTICLE; DRUG EFFICACY; INFECTION PREVENTION; MACACA FASCICULARIS; MONOTHERAPY; NEW ZEALAND WHITE (RABBIT); NONHUMAN; POST EXPOSURE PROPHYLAXIS; PRE-EXPOSURE PROPHYLAXIS; PRIORITY JOURNAL; SURVIVAL; ANIMAL; BACILLUS ANTHRACIS; BACTEREMIA; DISEASE MODEL; DRUG EFFECTS; FEMALE; INTRAMUSCULAR DRUG ADMINISTRATION; INTRAVENOUS DRUG ADMINISTRATION; MALE; MICROBIOLOGY; MORTALITY; PATHOGENICITY; RABBITS AND HARES; RESPIRATORY TRACT INFECTIONS; SURVIVAL RATE;

ANIMALS; ANTHRAX; ANTI-BACTERIAL AGENTS; ANTIBODIES, MONOCLONAL; ANTITOXINS; BACILLUS ANTHRACIS; BACTEREMIA; DISEASE MODELS, ANIMAL; FEMALE; INJECTIONS, INTRAMUSCULAR; INJECTIONS, INTRAVENOUS; MACACA FASCICULARIS; MALE; POST-EXPOSURE PROPHYLAXIS; PRE-EXPOSURE PROPHYLAXIS; RABBITS; RESPIRATORY TRACT INFECTIONS; SURVIVAL RATE;

EID: 84992379403     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.01102-16     Document Type: Article

References (34)

1. Guarner J, Jernigan JA, Shieh WJ, Tatti K, Flannagan LM, Stephens DS, Popovic T, Ashford DA, Perkins BA, Zaki SR. 2003. Pathology and pathogenesis of bioterrorism-related inhalational anthrax. Am J Pathol 163:701-709. http://dx.doi.org/10.1016/S0002-9440(10)63697-8.
2. Holty JE, Bravata DM, Liu H, Olshen RA, McDonald KM, Owens DK. 2006. Systematic review: a century of inhalational anthrax cases from 1900 to 2005. Ann Intern Med 144:270-280. http://dx.doi.org/10.7326/0003-4819-144-4-200602210-00009.
3. Adalja AA, Toner E, Inglesby TV. 2015. Management of potential bioterrorism-related conditions. N Engl J Med 372:2272-2273. http://dx.doi.org/10.1056/NEJMc1504248.
4. Bower WA, Hendricks K, Pillai S, Guarnizo J, Meaney-Delman D. 2015. Clinical framework and medical countermeasure use during an anthrax mass-casualty incident. MMWR Recomm Rep 64:1-22. http://dx.doi.org/10.15585/mmwr.rr6404a1.
5. Hendricks KA, Wright ME, Shadomy SV, Bradley JS, Morrow MG, Pavia AT, Rubinstein E, Holty JE, Messonnier NE, Smith TL, Pesik N, Treadwell TA, Bower WA. 2014. Centers for Disease Control and Prevention expert panel meetings on prevention and treatment of anthrax in adults. Emerg Infect Dis 20:e130687.
6. Pittman PR, Norris SL, Barrera Oro JG, Bedwell D, Cannon TL, McKee KT, Jr. 2006. Patterns of antibody response in humans to the anthrax vaccine adsorbed (AVA) primary (six-dose) series. Vaccine 24:3654-3660. http://dx.doi.org/10.1016/j.vaccine.2006.01.054.
7. Singer DE, Schneerson R, Bautista CT, Rubertone MV, Robbins JB, Taylor DN. 2008. Serum IgG antibody response to the protective antigen (PA) of Bacillus anthracis induced by anthrax vaccine adsorbed (AVA) among U.S. military personnel. Vaccine 26:869873.
8. Tsai CW, Morris S. 2015. Approval of raxibacumab for the treatment of inhalation anthrax under the US Food and Drug Administration "animal rule." Front Microbiol 6:1320.
9. Maynard JA, Maassen CB, Leppla SH, Brasky K, Patterson JL, Iverson BL, Georgiou G. 2002. Protection against anthrax toxin by recombinant antibody fragments correlates with antigen affinity. Nat Biotechnol 20:597-601. http://dx.doi.org/10.1038/nbt0602-597.
10. Rosovitz MJ. 2003. Alanine-scanning mutations in domain 4 of anthrax toxin protective antigen reveal residues important for binding to the cellular receptor and to a neutralizing monoclonal antibody. J Biol Chem 278:30936-30944. http://dx.doi.org/10.1074/jbc.M301154200.
11. Mohamed N, Clagett M, Li J, Jones S, Pincus S, D'Alia G, Nardone L, Babin M, Spitalny G, Casey L. 2005. A high-affinity monoclonal antibody to anthrax protective antigen passively protects rabbits before and after aerosolized Bacillus anthracis spore challenge. Infect Immun 73:795-802. http://dx.doi.org/10.1128/IAI.73.2.795-802.2005.
12. Vasconcelos D. 2003. Pathology of inhalation anthrax in cynomolgus monkeys (Macaca fascicularis). Lab Investig 83:1201-1209. http://dx.doi.org/10.1097/01.LAB.0000080599.43791.01.
13. Zaucha GM, Pitt LM, Estep J, Ivins BE, Friedlander AM. 1998. The pathology of experimental anthrax in rabbits exposed by inhalation and subcutaneous inoculation. Arch Pathol Lab Med 122:982-992.
14. Henning LN, Comer JE, Stark GV, Ray BD, Tordoff KP, Knostman KA, Meister GT. 2012. Development of an inhalational Bacillus anthracis exposure therapeutic model in cynomolgus macaques. Clin Vaccine Immunol 19:1765-1775. http://dx.doi.org/10.1128/CVI.00288-12.
15. U.S. FDA. 2001. Guidance for industry. Bioanalytical method validation. U.S. FDA, Washington, DC.
16. Lee JW, Hall M. 2009. Method validation of protein biomarkers in support of drug development or clinical diagnosis/prognosis. J Chromatogr B Analyt Technol Biomed Life Sci 877:1259-1271. http://dx.doi.org/10.1016/j.jchromb.2008.11.022.
17. Mehrotra DV, Chan IS, Berger RL. 2003. A cautionary note on exact unconditional inference for a difference between two independent binomial proportions. Biometrics 59:441450. http://dx.doi.org/10.1111/1541-0420.00051.
18. Boag JW. 1949. Maximum likelihood estimates of the proportion of patients cured by cancer therapy. J R Stat Soc 11:15-53.
19. Farewell VT. 1982. The use of mixture models for the analysis of survival data with long-term survivors. Biometrics 38:1041-1046. http://dx.doi.org/10.2307/2529885.
20. U.S. FDA. 2016. Anthrax: developing drugs for prophylaxis of inhalational anthrax; guidance for industry. U.S. FDA, Washington, DC.
21. Lincoln RE, Hodges DR, Klein F, Mahlandt BG, Jones WI, Jr, Haines BW, Rhian MA, Walker JS. 1965. Role of the lymphatics in the pathogenesis of anthrax. J Infect Dis 115:481-494. http://dx.doi.org/10.1093/infdis/115.5.481.
22. Ohanjanian L, Remy KE, Li Y, Cui X, Eichacker PQ. 2015. An overview of investigational toxin-directed therapies for the adjunctive management of Bacillus anthracis infection and sepsis. Expert Opin Investig Drugs 24:851-865. http://dx.doi.org/10.1517/13543784.2015.1041587.
23. Weiss S, Kobiler D, Levy H, Pass A, Ophir Y, Rothschild N, Tal A, Schlomovitz J, Altboum Z. 2011. Antibiotics cure anthrax in animal models. Antimicrob Agents Chemother 55:1533-1542. http://dx.doi.org/10.1128/AAC.01689-10.
24. Migone TS, Subramanian GM, Zhong J, Healey LM, Corey A, Devalaraja M, Lo L, Ullrich S, Zimmerman J, Chen A, Lewis M, Meister G, Gillum K, Sanford D, Mott J, Bolmer SD. 2009. Raxibacumab for the treatment of inhalational anthrax. N Engl J Med 361:135-144. http://dx.doi.org/10.1056/NEJMoa0810603.
25. Quinn CP, Sabourin CL, Niemuth NA, Li H, Semenova VA, Rudge TL, Mayfield HJ, Schiffer J, Mittler RS, Ibegbu CC, Wrammert J, Ahmed R, Brys AM, Hunt RE, Levesque D, Estep JE, Barnewall RE, Robinson DM, Plikaytis BD, Marano N. 2012. A three-dose intramuscular injection schedule of anthrax vaccine adsorbed generates sustained humoral and cellular immune responses to protective antigen and provides long-term protection against inhalation anthrax in rhesus macaques. Clin Vaccine Immunol 19:1730-1745. http://dx.doi.org/10.1128/CVI.00324-12.
26. Friedlander AM, Welkos SL, Pitt ML, Ezzell JW, Worsham PL, Rose KJ, Ivins BE, Lowe JR, Howe GB, Mikesell P, Lawrence WB. 1993. Postexposure prophylaxis against experimental inhalation anthrax. J Infect Dis 167:1239-1243. http://dx.doi.org/10.1093/infdis/167.5.1239.
27. Henderson DW, Peacock S, Belton FC. 1956. Observations on the prophylaxis of experimental pulmonary anthrax in the monkey. J Hyg (Lond) 54:28-36. http://dx.doi.org/10.1017/S0022172400044272.
28. Vietri NJ, Purcell BK, Tobery SA, Rasmussen SL, Leffel EK, Twenhafel NA, Ivins BE, Kellogg MD, Webster WM, Wright ME, Friedlander AM. 2009. A short course of antibiotic treatment is effective in preventing death from experimental inhalational anthrax after discontinuing antibiotics. J Infect Dis 199:336-341. http://dx.doi.org/10.1086/596063.
29. Drusano GL, Okusanya OO, Okusanya A, Van Scoy B, Brown DL, Kulawy R, Sorgel F, Heine HS, Louie A. 2008. Is 60 days of ciprofloxacin administration necessary for postexposure prophylaxis for Bacillus anthracis? Antimicrob Agents Chemother 52:3973-3979. http://dx.doi.org/10.1128/AAC.00453-08.
30. Gutting BW, Nichols TL, Channel SR, Gearhart JM, Andrews GA, Berger AE, Mackie RS, Watson BJ, Taft SC, Overheim KA, Sherwood RL. 2012. Inhalational anthrax (Ames aerosol) in naive and vaccinated New Zealand rabbits: characterizing the spread of bacteria from lung deposition to bacteremia. Front Cell Infect Microbiol 2:87.
31. Ionin B, Hopkins RJ, Pleune B, Sivko GS, Reid FM, Clement KH, Rudge TL, Jr, Stark GV, Innes A, Sari S, Guina T, Howard C, Smith J, Swoboda ML, Vert-Wong E, Johnson V, Nabors GS, Skiadopoulos MH. 2013. Evaluation of immunogenicity and efficacy of anthrax vaccine adsorbed for postexposure prophylaxis. Clin Vaccine Immunol 20:1016-1026. http://dx.doi.org/10.1128/CVI.00099-13.
32. Liu S, Moayeri M, Leppla SH. 2014. Anthrax lethal and edema toxins in anthrax pathogenesis. Trends Microbiol 22:317-325. http://dx.doi.org/10.1016/j.tim.2014.02.012.
33. Lovchik JA, Drysdale M, Koehler TM, Hutt JA, Lyons CR. 2012. Expression of either lethal toxin or edema toxin by Bacillus anthracis is sufficient for virulence in a rabbit model of inhalational anthrax. Infect Immun 80:2414-2425. http://dx.doi.org/10.1128/IAI.06340-11.
34. Yamamoto BJ, Shadiack AM, Carpenter S, Sanford D, Henning LN, O'Connor E, Gonzales N, Mondick J, French J, Stark GV, Fisher AC, Casey LS, Serbina NV. 2016. Efficacy projection of obiltoxaximab for treatment of inhalational anthrax across a range of disease severity. Antimicrob Agents Chemother 60:5787-5795. http://dx.doi.org/10.1128/AAC.00972-16.